Therapeutic CD154 antibody for lupus: promise for the future?

AUTOR(ES)

Kelsoe, Garnett

FONTE

American Society for Clinical Investigation

RESUMO

Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease characterized by the production of pathogenic autoantibodies. A new study demonstrates that passive antibody specific for the TNF family member, CD154, ameliorates disease by reducing levels of self-reactive antibody in the serum. This study demonstrates a substantial potential for anti-CD154 antibody in the treatment of humoral autoimmunity.

Documentos Relacionados

• The role of CD154 in organ transplant rejection and acceptance.
• Delineation of a Novel Pathway That Regulates CD154 (CD40 Ligand) Expression
• Delineation of a Novel Pathway That Regulates CD154 (CD40 Ligand) Expression
• CD28 and inducible costimulator (ICOS) signalling can sustain CD154 expression on activated T cells
• CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes